Brokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Price Target at $24.67

RAPT Therapeutics, Inc. (NASDAQ:RAPTGet Free Report) has been given a consensus recommendation of “Hold” by the thirteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $24.67.

Several research firms have weighed in on RAPT. UBS Group downgraded RAPT Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $61.00 to $10.00 in a research note on Thursday, February 22nd. Evercore ISI began coverage on RAPT Therapeutics in a research note on Friday, February 16th. They set an “outperform” rating on the stock. SVB Leerink downgraded RAPT Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $42.00 to $10.00 in a research note on Wednesday, February 21st. Wolfe Research reiterated a “peer perform” rating on shares of RAPT Therapeutics in a research note on Tuesday, May 14th. Finally, HC Wainwright reiterated a “neutral” rating on shares of RAPT Therapeutics in a research note on Wednesday, April 10th.

Check Out Our Latest Stock Analysis on RAPT Therapeutics

Hedge Funds Weigh In On RAPT Therapeutics

Hedge funds have recently bought and sold shares of the business. Swiss National Bank boosted its position in RAPT Therapeutics by 9.6% during the third quarter. Swiss National Bank now owns 49,100 shares of the company’s stock worth $816,000 after purchasing an additional 4,300 shares in the last quarter. TimesSquare Capital Management LLC purchased a new position in RAPT Therapeutics during the fourth quarter worth approximately $12,533,000. FMR LLC boosted its position in RAPT Therapeutics by 7.4% during the third quarter. FMR LLC now owns 4,499,293 shares of the company’s stock worth $74,778,000 after purchasing an additional 308,804 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in RAPT Therapeutics by 347.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,981 shares of the company’s stock worth $99,000 after purchasing an additional 3,092 shares in the last quarter. Finally, Braidwell LP boosted its position in RAPT Therapeutics by 10.0% during the third quarter. Braidwell LP now owns 1,082,512 shares of the company’s stock worth $17,991,000 after purchasing an additional 98,112 shares in the last quarter. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Price Performance

Shares of NASDAQ:RAPT opened at $4.08 on Friday. The business’s 50-day moving average is $7.18 and its 200 day moving average is $14.44. RAPT Therapeutics has a 1 year low of $3.95 and a 1 year high of $27.35. The firm has a market capitalization of $142.22 million, a P/E ratio of -1.33 and a beta of 0.52.

RAPT Therapeutics (NASDAQ:RAPTGet Free Report) last announced its earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.05. On average, analysts expect that RAPT Therapeutics will post -2.94 EPS for the current year.

RAPT Therapeutics Company Profile

(Get Free Report

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Recommended Stories

Analyst Recommendations for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.